Get a glimpse into our company and investor data—powered by the PitchBook Platform
Developer of therapeutics designed to stop the progression of cancer and activate the healthy immune system. The company's services uses active ingredients are based on Angiocidin, a protein which has been shown to activate monocytes and drive terminal differentiation of leukemia cells, enabling AML patients to get proper treatement against cancer.
You’re viewing a free company profile from the PitchBook Platform. To explore Diffregen’s full profile, request a free trial.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Accelerator/Incubator | 21-Feb-2018 | Completed | Startup | |||
2. Grant | 01-Jan-2013 | 00000 | Completed | Startup | ||
1. Grant | 01-Jan-2011 | $100K | Completed | Startup |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
---|---|---|---|---|---|---|
MassChallenge | Accelerator/Incubator | 000 0000 | 000000 0 | |||
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | |||
Science Center | Accelerator/Incubator | 000 0000 | 000000 0 |